常晖 职务：
职称：副主任医师
专长：盆腔肿瘤（宫颈癌、直肠癌）、鼻咽癌等的放射治疗

主要简介 详细介绍 预约挂号

2011年北京协和医学院临床医学博士毕业，现任中山大学肿瘤防治中心放疗科副主任医师、硕士生导师。主要研究方向为盆腔肿瘤（宫颈癌、直肠癌）及鼻咽癌等的放射治疗及综合治疗。以第一作者或通讯作者发表高水平收录论文10余篇，主持或参与多项国家级、省部级科研课题。

一、主要研究方向
宫颈癌的放化疗
直肠癌的放化疗及放疗抵抗
鼻咽癌的放化疗

二、学习工作经历
2003.09 至 2011.07，北京协和医学院，临床医学（八年制），博士
2011.08 至 2014.12，中山大学肿瘤防治中心，住院医师
2014.12 至 2019.12，中山大学肿瘤防治中心，主治医师
2019.12 至 今，中山大学肿瘤防治中心，副主任医师

三、学术兼职
广东省抗癌协会放疗专业委员会青年委员会，委员
广东省中西医结合协会放射治疗专业委员会，委员

四、在研课题
广东省自然科学基金面上项目，2020A，CCR6/CDC7通路调控DNA损伤修复介导直肠癌放射抗拒的机制研究，2019/10至2022/09，10万元，主持

五、近三年发表论文
[1] Chang H#, Tao YL#, Ye WJ, Xiao WW, Xia YF, Gao YH*. Regular aspirin intake and prognosis of TxN2-3M0 nasopharyngeal carcinoma: A cohort study based on propensity score matching. Oral Oncol. 2020; 103: 104589.
[2] Chang H#, Wang GN#, Tao YL*. The expression of long noncoding RNA CRCAL-3 in colorectal cancer and its impacts on cell proliferation and migration. J Cell Biochem. 2019; 120(9): 15369-15377.
[3] Chang H# , Peng L#, Tao YL#, Chen C, Xiao WW, Hu YH*, Gao YH*. Necessity of concurrent chemotherapy in N2-3 nasopharyngeal carcinoma treated with neoadjuvant chemotherapy of ≥ 3 cycles followed by intensity-modulated radiotherapy. Cancer Med. 2019; 8(6): 2823-2831.
[4] Chang H#, Chen K#, Lin YZ, Tao YL, Liu Y, Cao XP*, Ye WJ*. Prognostic value of serum apolipoprotein A-I in locally advanced cervical squamous cell carcinoma treated with radical chemoradiotherapy. Transl Cancer Res. 2018; 7(6): 1474-1481.
[5] Chang H#, Liu YB#, Yi W, Lu JB, Zhang JX*. Development and validation of a model to predict tyrosine kinase inhibitor-sensitive EGFR mutations of non-small cell lung cancer based on multi-institutional data. Thorac Cancer. 2018; 9(12): 1680-1686.
[6] Chang H#, Wei JW#, Tao YL, Ding PR, Xia YF, Gao YH*, Xiao WW*. CCR6 Is a Predicting Biomarker of Radiosensitivity and Potential Target of Radiosensitization in Rectal Cancer. Cancer Res Treat. 2018; 50(4): 1203-1213.
[7] Chang H#, Yu X#, Chen K, Wang QX, Zhang S, Zeng ZF, Ding PR, Pan ZZ, Xiao WW*, Gao YH*. Prognostic Value of the Cycle Number of Perioperative Chemotherapy in Locoregionally Advanced Rectal Cancer: a Propensity Score Matching Analysis. J Cancer. 2018; 9(23): 4346-4354.
[8] Chang H#, Jiang W#, Ye WJ, Tao YL, Wang QX, Xiao WW*, Gao YH*. Is long interval from neoadjuvant chemoradiotherapy to surgery optimal for rectal cancer in the era of intensity-modulated radiotherapy?: a prospective observational study. Onco Targets Ther. 2018; 11: 6129-6138.
[9] Chang H#, Yi W#, Wang X, Tao Y, Yang X, Chen C, Zhang W, Zhou S, Liu S, Li X, Ding S, Li J, Li G, Shao X, Liu Y, Song W, Xia Y*. Effectiveness and safety of different amifostine regimens: Preliminary results of a phase II multicenter randomized controlled trial. Chin J Cancer Res. 2018; 30(3): 307-314.
[10] Chang H#, Wei JW, Chen K, Zhang S, Han F, Lu LX, Xiao WW*, Gao YH*. Apolipoprotein A-I Is a Prognosticator of Nasopharyngeal Carcinoma in the Era of Intensity-modulated Radiotherapy. J Cancer. 2018; 9(4): 702-710.
[11] Chang H#, Yu X#, Xiao WW, Wang QX, Zhou WH, Zeng ZF, Ding PR, Li LR*, Gao YH*. Neoadjuvant chemoradiotherapy followed by surgery in patients with unresectable locally advanced colon cancer: a prospective observational study. Onco Targets Ther. 2018; 11: 409-418.

更新日期：2020年5月30日